Avacta inks multi-million dollar deal with US biotech firm
Diagnostics specialist Avacta has signed an agreement with US biotech companny Moderna Therapeutics which could be worth tens of millions of dollars.
Under the terms of the collaboration, licensing and option agreement, Moderna will make an upfront payment of $500,000 to provide it with exclusive access to Affimers, Avacta’s product.
Affimers are engineered proteins that mimic the specificity and binding affinities of antibodies, but are much smaller, more robust and simpler to produce.